Akron Bio’s new facility in Sarasota, FL will address critical demands in the rapidly growing gene therapy and vaccine markets by providing plasmid DNA, an important ancillary material used in the manufacture of advanced therapies. Learn more about the new facility here: https://akronbiotech.com/pdna-manufacturing/cgmp-facility-and-infrastructure
At the 2021 Treg Directed Therapies Summit, Dr. Sara Padrell Sánchez discusses bringing next-generation solutions to Treg therapies. Learn more about the summit here: https://treg-directed-therapies.com/
In a Phacilitate webinar titled "What are the key decision points when sourcing plasmid DNA?" Ricardo Jimenez (VP of Technical Operations, Neurogene Inc), Sebastian Almeida (Director of Manufacturing and CMC, Akron Biotech), and Donald W. Fink, Ph.D. (Master Practice Expert, Dark Horse Consulting) share lessons learned about pDNA manufacturing design from the commercial perspective. Moderated by Akron President & Chief Commercial Officer David Smith. For more details, visit https://www.phacilitate.co.uk/article/webinar-how-choose-quality-grade-pdna-right-manufacturer
At the 2021 Allogeneic Cell Therapies Summit, Dr. Ezequiel Zylberberg discusses bringing liquid cGMP cytokines and growth factors into functionally closed, single-use systems for ex vivo applications. Learn more about the summit here: https://allogeneic-cell-therapies.com/
At the Innate Killer Summit 2021, Sara Padrell Sánchez, Ph.D., Akron's Business Development Director, Europe, addressed key industry bottlenecks—like GMP Plasmid DNA manufacturing—and how Akron Biotech develops systems, solutions, and regulatory support to meet these challenges head-on. For more information about the virtual event, visit: www.innate-killer.com
On October 13, 2020, at ARM's Cell & Gene Meeting on the Mesa 2020, Akron Biotech CEO Claudia Zylberberg joined Terumo Blood and Cell Technologies' Delara Motlagh and NIIMBL's Kelvin Lee for a discussion about the challenges, scalability, standards, and issues around GMP manufacturing of cell and gene therapies.